PMG-1015 / Pulmongene - LARVOL DELTA

A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects (clinicaltrials.gov) - P1 | N=29 | Completed | Sponsor: Pulmongene Ltd. | Recruiting ➔ Completed | Trial completion date: May 2025 ➔ Feb 2025

Trial completion • Trial completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Late Breaking Abstract - PMG1015 demonstrates well-tolerated safety and favorable FVC changes after 12 weeks of treatment in IPF Patients (ERS 2025) - P1 | "PMG1015 demonstrated excellent safety and tolerability with minimal immunogenicity in IPF patients. The favorable FVC and CT imaging changes support continued clinical development of PMG1015 as a monotherapy or combination therapy for IPF."

Clinical • Late-breaking abstract • Idiopathic Pulmonary Fibrosis • Immunology • AREG

Safety, Tolerability, and Clinical Pharmacology of PMG1015: An Anti-Amphiregulin Antibody as a Novel Treatment for Idiopathic Pulmonary Fibrosis (ATS 2025) - P1a | "PMG1015 is safe and well-tolerated with favorable pharmacokinetic characteristics in healthy volunteers. These results support the progression of PMG1015 to further studies in patients with IPF."

Clinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study of PMG1015 Injection in Idiopathic Pulmonary Fibrosis Subjects (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Pulmongene Ltd.

New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • MB

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 (clinicaltrials.gov) - P1a | N=54 | Completed | Sponsor: Pulmongene Ltd. | Recruiting ➔ Completed

Trial completion • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases